EvoEndo Elects David Pierce to the Board of Directors
03 May 2023
Executive Change
DENVER--(BUSINESS WIRE)-- EvoEndo®, Inc. (“EvoEndo”), a medical device company developing platforms for Unsedated Transnasal Endoscopy (TNE), is proud to announce that David Pierce has joined our Board of Directors.
Mr. Pierce brings a wealth of experience and wisdom from his 30-year track record of success at Boston Scientific and his current activity as an Independent Trustee with Diversified Healthcare Trust. He has a deep level of knowledge in the field of endoscopy and understands what it takes to drive long-term profitable growth.
During his long tenure at Boston Scientific, Mr. Pierce’s roles included Executive Vice President and President of MedSurg, President of Endoscopy, Senior Vice President and President of the Urology Division, and Senior Vice President and President of the Endoscopy Division.
“We are extremely pleased to have the opportunity to work with Dave Pierce,” said CEO Jonathan Hartmann. “Dave understands how to successfully penetrate and grow new markets with novel technologies aimed at providing patients and physicians with exceptional clinical outcomes.”
Mr. Pierce is a trustee of Norwich University and previously served as a director of the Medical Device Manufacturers Association and MassMedic. He was the strategic advisory board chair of the American Gastroenterology Association Center for GI Innovation and a director of the American Society of Gastrointestinal Endoscopy Foundation. Mr. Pierce attained the rank of Captain in the United States Army.
Mr. Pierce's experience, leadership, and accomplishments will be extremely valuable to EvoEndo as we execute our mission of enabling unsedated endoscopy.
About EvoEndo®
EvoEndo®, Inc. is a medical device company developing sterile single-use, flexible endoscopes that enable unsedated endoscopic procedures. EvoEndo’s technology allows pediatric patients and adults to consider an unsedated option for routine endoscopies in a clinic setting without general anesthesia or sedation. To learn more, please visit .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.